Disc Medicine, Inc. last reported quarterly results on Oct 22, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026). It usually reports 12–35 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–35 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 22, 2026
22 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
—
|
—
|
—
|
|
Jul 30, 2026
30 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-60
-7.8%
|
-1.54
+2.5%
|
|
May 5, 2026
35 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-64
-86.3%
|
-1.65
-61.8%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
—
|
-61
-105.5%
|
-1.61
-63.8%
|
|
Oct 20, 2025
20 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
—
|
-62
-134.3%
|
-1.77
-98.9%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
—
|
-55
-109.7%
|
-1.58
-53.4%
|
|
May 7, 2025
37 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
-34
-26.5%
|
-1.02
+6.4%
|
|
Feb 27, 2025
58 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
—
|
-29
-24.9%
|
-0.98
-1.8%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IRON (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Watertown, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1816736
- Former names
- Gemini Therapeutics, Inc. /DE (until Dec 28, 2022); FS Development Corp. (until Feb 8, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.